Navigation Links
Spectros Corporation Signs Distribution Agreements in Middle East

PORTOLA VALLEY, Calif., Dec. 6, 2011 /PRNewswire/ -- Spectros Corporation announced today an expansion of its distribution channels in the Middle East with the signing of distributors based in the UAE, with expansion to other areas of the Middle East under discussion. These groups will join other distributors already selling Spectros products outside of the U.S.

"We are excited by this continued expansion," noted Director of Sales Elizabeth van Thillo-Rohlff. "More and more physicians are recognizing the opportunity offered by the superior Spectros T-Stat® tissue oximeter, as was confirmed in recent independent studies."

Spectros T-Stat Oximeter is currently the only broadband tissue oximeter on the market in the U.S. and Europe. T-Stat competes in the marketplace with INVOS® oximeters marketed by Covidien, and FORE-SIGHT® oximeters marketed by CAS Medical. In reconstructive surgery, T-Stat competes with oximeters marketed by ViOptix.

An expanded array of probes, including broadband infrared Continuum® monitor, Ceres™ cerebral probes, and multi-site T-Stat monitors are currently in testing, pending FDA approval and release anticipated over the next year.

About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue.  T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art broadband visible light spectroscopy (VLS). The non-invasive T-Stat system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing oximeter product lines that only use 2-4.

Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute.  Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note:  Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns.  Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled "for investigational use only." T-Stat, Continuum, and CereS are trademarks of the Spectros Corporation. INVOS is a trademark of Somanetics and Covidien. FORE-SIGHT is a trademark of CAS Medical).

For further information, visit

SOURCE Spectros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Spectros Signs New International Distribution Deals
2. Spectros Signs New International Distribution Deals
3. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
4. Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results
5. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
6. delSECUR CORPORATION Announces Appointment of the Companys President & CEO
7. $29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation
8. delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation
9. delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation
10. M2SYS Biometric Software Solution Selected By GHG Corporation
11. Harris Corporation Adds Broadband Satellite Data Mode to JTRS-Approved Falcon III(R) AN/PRC-117G Multiband Manpack Radio
Post Your Comments:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology: